title: Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
abstract: Patients with advanced systemic mastocytosis, including mast cell leukemia, have a poor prognosis. In these patients, neoplastic mast cells usually harbor the KIT mutant D816V that confers resistance against tyrosine kinase inhibitors. We examined the effects of the multi-kinase blocker ponatinib on neoplastic mast cells and investigated whether ponatinib acts synergistically with other antineoplastic drugs. Ponatinib was found to inhibit the kinase activity of KIT G560V and KIT D816V in the human mast cell leukemia cell line HMC-1. In addition, ponatinib was found to block Lyn- and STAT5 activity in neoplastic mast cells. Ponatinib induced growth inhibition and apoptosis in HMC-1.1 cells (KIT G560V(+)) and HMC-1.2 cells (KIT G560V(+)/KIT D816V(+)) as well as in primary neoplastic mast cells. The effects of ponatinib were dose-dependent, but higher IC50-values were obtained in HMC-1 cells harboring KIT D816V than in those lacking KIT D816V. In drug combination experiments, ponatinib was found to synergize with midostaurin in producing growth inhibition and apoptosis in HMC-1 cells and primary neoplastic mast cells. The ponatinib+midostaurin combination induced substantial inhibition of KIT-, Lyn-, and STAT5 activity, but did not suppress Btk. We then applied a Btk short interfering RNA and found that Btk knockdown sensitizes HMC-1 cells against ponatinib. Finally, we were able to show that ponatinib synergizes with the Btk-targeting drug dasatinib to produce growth inhibition in HMC-1 cells. In conclusion, ponatinib exerts major growth-inhibitory effects on neoplastic mast cells in advanced systemic mastocytosis and synergizes with midostaurin and dasatinib in inducing growth arrest in neoplastic mast cells.
authors.affiliation: Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.
authors.forename: Karoline V
authors.initials: KV
authors.lastname: Gleixner
authors.forename: Barbara
authors.initials: B
authors.lastname: Peter
authors.forename: Katharina
authors.initials: K
authors.lastname: Blatt
authors.forename: Verena
authors.initials: V
authors.lastname: Suppan
authors.forename: Andreas
authors.initials: A
authors.lastname: Reiter
authors.forename: Deepti
authors.initials: D
authors.lastname: Radia
authors.forename: Emir
authors.initials: E
authors.lastname: Hadzijusufovic
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D045744:Cell Line, Tumor; D004357:Drug Synergism; D005260:Female; D006131:Growth Inhibitors / Q000008:administration & dosage*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D034721:Mastocytosis, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011724:Pyridazines / Q000008:administration & dosage*; D019311:Staurosporine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib; D019009:Proto-Oncogene Proteins c-kit; D019311:Staurosporine; C059539:midostaurin
references.citation: Cancer Cell. 2009 Nov 6;16(5):401-12
references.pmid: 19878872
references.citation: Exp Hematol. 2010 Sep;38(9):744-55
references.pmid: 20553795
references.citation: Mol Cancer Ther. 2002 Oct;1(12):1115-24
references.pmid: 12481435
references.citation: Blood. 2006 Jul 1;108(1):286-91
references.pmid: 16434489
references.citation: Haematologica. 2011 Mar;96(3):459-63
references.pmid: 21134978
references.citation: Mol Cancer Ther. 2011 Jun;10(6):1028-35
references.pmid: 21482694
references.citation: Am J Pathol. 2009 Dec;175(6):2416-29
references.pmid: 19893034
references.citation: J Allergy Clin Immunol. 2004 Jul;114(1):3-11; quiz 12
references.pmid: 15241337
references.citation: Blood. 2008 Mar 15;111(6):3097-107
references.pmid: 18180381
references.citation: Blood. 2008 Aug 15;112(4):946-56
references.pmid: 18684881
references.citation: Expert Rev Hematol. 2010 Aug;3(4):497-516
references.pmid: 21083038
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3906-15
references.pmid: 18559612
references.citation: Blood. 2006 Jan 15;107(2):752-9
references.pmid: 16189265
references.citation: Br J Haematol. 2001 May;113(2):357-64
references.pmid: 11380399
references.citation: Leukemia. 2009 May;23(5):900-4
references.pmid: 19262599
references.citation: Leuk Res. 2003 Jul;27(7):635-41
references.pmid: 12681363
references.citation: Exp Hematol. 2003 Aug;31(8):686-92
references.pmid: 12901973
references.citation: Blood. 2007 Dec 1;110(12):4055-63
references.pmid: 17720881
references.citation: N Engl J Med. 2012 Nov 29;367(22):2075-88
references.pmid: 23190221
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8
references.pmid: 17684099
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: J Clin Invest. 1993 Oct;92(4):1736-44
references.pmid: 7691885
references.citation: Blood. 2003 Dec 15;102(13):4270-6
references.pmid: 12933573
references.citation: Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10560-4
references.pmid: 7479840
references.citation: Blood. 2005 Jul 15;106(2):721-4
references.pmid: 15790786
references.citation: Best Pract Res Clin Haematol. 2006;19(3):595-615
references.pmid: 16781490
references.citation: Blood. 2011 Aug 18;118(7):1885-98
references.pmid: 21680801
references.citation: Leuk Res. 1988;12(4):345-55
references.pmid: 3131594
references.citation: Leukemia. 2012 Jul;26(7):1693-5
references.pmid: 22301675
references.citation: Blood. 2005 Oct 15;106(8):2865-70
references.pmid: 15972446
references.citation: Leuk Res. 2011 Sep;35(9):1143-52
references.pmid: 21641642
references.citation: Annu Rev Med. 2004;55:419-32
references.pmid: 14746529
references.citation: Blood. 2009 Jun 4;113(23):5727-36
references.pmid: 19363219